Alzheimer’s drug receives positive results from Phase II study

Written by Sharon Salt, Editor

Eisai Co., Ltd. (Tokyo, Japan) and Biogen Inc. (MA, USA) have announced positive topline results from a Phase II study with BAN2401 – an anti-amyloid beta protofibril antibody – in subjects with early Alzheimer’s disease (AD). The study is a placebo-controlled, double-blind, parallel-group, randomized trial that examined 856 individuals with early AD. According to the researchers, the study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in AD Composite Score (ADCOMS), and on reduction of amyloid accumulated in the brain, as measured using amyloid-PET. In December 2017, the study did not achieve its...

To view the full article, please register now for access

It's completely free